Sorbonne Paris Cité, Laboratoire de Pathologie, Université Paris Diderot, Paris, France
Medical Oncology Department, National Cancer Hospital, Ha Noi, Viet Nam
Sorbonne Paris Cité, Laboratoire de Pathologie, Université Paris Diderot, Paris, France
Sorbonne Paris Cité, Laboratoire de Pathologie, Université Paris Diderot, Paris, France
Sorbonne Paris Cité, Laboratoire de Pathologie, Université Paris Diderot, Paris, France
Sorbonne Paris Cité, Laboratoire de Pathologie, Université Paris Diderot, Paris, France
Sorbonne Paris Cité, Laboratoire de Pathologie, Université Paris Diderot, Paris, France
INSERM, Paris, France
Oncology Department, Ha Noi Medical University, Ha Noi, Viet Nam
Laboratoire de Pathologie, AP-HP-Hopital Saint-Louis, Paris, France
Service d’Oncologie, AP-HP-Hopital Avicenne, Bobigny, France
Léonard de Vinci, Université Paris 13, Villetaneuse, France
Copyright © 2016 Tu V. Dao, Thuan V. Tran, Christophe Lebœuf, Morad El-Bouchtaoui, Jérôme Verine, Anne Janin, Guilhem Bousquet et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Dao, T. , Tran, T. , Lebœuf, C. , El-Bouchtaoui, M. , Verine, J. , Janin, A. and Bousquet, G. (2016) Sorafenib Acts through VEGFR-2 Inhibition in a Metastatic Clear-Cell Sarcoma of the Kidney.
Journal of Cancer Therapy,
7, 487-493. doi:
10.4236/jct.2016.77051.